Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis

Holly J. Garringer, Mahdi Malekpour, Fatemehsadat Esteghamat, Seyed M.J. Mortazavi, Siobhan I. Davis, Emily G. Farrow, Xijie Yu, Dan E. Arking, Harry C. Dietz, Kenneth E. White

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Fibroblast growth factor 23 (FGF23) is a hormone required for normal renal phosphate reabsorption. FGF23 gain-of-function mutations result in autosomal dominant hypophosphatemic rickets (ADHR), and FGF23 loss-of-function mutations cause familial hyperphosphatemic tumoral calcinosis (TC). In this study, we identified a novel recessive FGF23 TC mutation, a lysine (K) substitution for glutamine (Q) (160 C > A) at residue 54 (Q54K). To understand the molecular consequences of all known FGF23-TC mutants (H41Q, S71G, M96T, S129F, and Q54K), these proteins were stably expressed in vitro. Western analyses revealed minimal amounts of secreted intact protein for all mutants, and ELISA analyses demonstrated high levels of secreted COOH-terminal FGF23 fragments but low amounts of intact protein, consistent with TC patients' FGF23 serum profiles. Mutant protein function was tested and showed residual, yet decreased, bioactivity compared with wildtype protein. In examining the role of the FGF23 COOH-terminal tail (residues 180-251) in protein processing and activity, truncated mutants revealed that the majority of the residues downstream from the known FGF23 SPC protease site (176RXXR179/S 180) were not required for protein secretion. However, residues adjacent to the RXXR site (between residues 188 and 202) were required for full bioactivity. In summary, we report a novel TC mutation and demonstrate a common defect of reduced FGF23 stability for all known FGF23-TC mutants. Finally, the majority of the COOH-terminal tail of FGF23 is not required for protein secretion but is required for full bioactivity.

Original languageEnglish (US)
Pages (from-to)E929-E937
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume295
Issue number4
DOIs
StatePublished - Oct 1 2008

Fingerprint

Calcinosis
Molecular Biology
Mutation
Proteins
Mutant Proteins
fibroblast growth factor 23
Glutamine
Lysine
Peptide Hydrolases

Keywords

  • Fibroblast growth factor 23
  • Hyperphosphatemia
  • Klotho
  • Phosphate

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Endocrinology, Diabetes and Metabolism

Cite this

Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis. / Garringer, Holly J.; Malekpour, Mahdi; Esteghamat, Fatemehsadat; Mortazavi, Seyed M.J.; Davis, Siobhan I.; Farrow, Emily G.; Yu, Xijie; Arking, Dan E.; Dietz, Harry C.; White, Kenneth E.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 295, No. 4, 01.10.2008, p. E929-E937.

Research output: Contribution to journalArticle

Garringer, Holly J. ; Malekpour, Mahdi ; Esteghamat, Fatemehsadat ; Mortazavi, Seyed M.J. ; Davis, Siobhan I. ; Farrow, Emily G. ; Yu, Xijie ; Arking, Dan E. ; Dietz, Harry C. ; White, Kenneth E. / Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis. In: American Journal of Physiology - Endocrinology and Metabolism. 2008 ; Vol. 295, No. 4. pp. E929-E937.
@article{3a92fce6592c4116a746e4bdae05e871,
title = "Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis",
abstract = "Fibroblast growth factor 23 (FGF23) is a hormone required for normal renal phosphate reabsorption. FGF23 gain-of-function mutations result in autosomal dominant hypophosphatemic rickets (ADHR), and FGF23 loss-of-function mutations cause familial hyperphosphatemic tumoral calcinosis (TC). In this study, we identified a novel recessive FGF23 TC mutation, a lysine (K) substitution for glutamine (Q) (160 C > A) at residue 54 (Q54K). To understand the molecular consequences of all known FGF23-TC mutants (H41Q, S71G, M96T, S129F, and Q54K), these proteins were stably expressed in vitro. Western analyses revealed minimal amounts of secreted intact protein for all mutants, and ELISA analyses demonstrated high levels of secreted COOH-terminal FGF23 fragments but low amounts of intact protein, consistent with TC patients' FGF23 serum profiles. Mutant protein function was tested and showed residual, yet decreased, bioactivity compared with wildtype protein. In examining the role of the FGF23 COOH-terminal tail (residues 180-251) in protein processing and activity, truncated mutants revealed that the majority of the residues downstream from the known FGF23 SPC protease site (176RXXR179/S 180) were not required for protein secretion. However, residues adjacent to the RXXR site (between residues 188 and 202) were required for full bioactivity. In summary, we report a novel TC mutation and demonstrate a common defect of reduced FGF23 stability for all known FGF23-TC mutants. Finally, the majority of the COOH-terminal tail of FGF23 is not required for protein secretion but is required for full bioactivity.",
keywords = "Fibroblast growth factor 23, Hyperphosphatemia, Klotho, Phosphate",
author = "Garringer, {Holly J.} and Mahdi Malekpour and Fatemehsadat Esteghamat and Mortazavi, {Seyed M.J.} and Davis, {Siobhan I.} and Farrow, {Emily G.} and Xijie Yu and Arking, {Dan E.} and Dietz, {Harry C.} and White, {Kenneth E.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1152/ajpendo.90456.2008",
language = "English (US)",
volume = "295",
pages = "E929--E937",
journal = "American Journal of Physiology",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis

AU - Garringer, Holly J.

AU - Malekpour, Mahdi

AU - Esteghamat, Fatemehsadat

AU - Mortazavi, Seyed M.J.

AU - Davis, Siobhan I.

AU - Farrow, Emily G.

AU - Yu, Xijie

AU - Arking, Dan E.

AU - Dietz, Harry C.

AU - White, Kenneth E.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Fibroblast growth factor 23 (FGF23) is a hormone required for normal renal phosphate reabsorption. FGF23 gain-of-function mutations result in autosomal dominant hypophosphatemic rickets (ADHR), and FGF23 loss-of-function mutations cause familial hyperphosphatemic tumoral calcinosis (TC). In this study, we identified a novel recessive FGF23 TC mutation, a lysine (K) substitution for glutamine (Q) (160 C > A) at residue 54 (Q54K). To understand the molecular consequences of all known FGF23-TC mutants (H41Q, S71G, M96T, S129F, and Q54K), these proteins were stably expressed in vitro. Western analyses revealed minimal amounts of secreted intact protein for all mutants, and ELISA analyses demonstrated high levels of secreted COOH-terminal FGF23 fragments but low amounts of intact protein, consistent with TC patients' FGF23 serum profiles. Mutant protein function was tested and showed residual, yet decreased, bioactivity compared with wildtype protein. In examining the role of the FGF23 COOH-terminal tail (residues 180-251) in protein processing and activity, truncated mutants revealed that the majority of the residues downstream from the known FGF23 SPC protease site (176RXXR179/S 180) were not required for protein secretion. However, residues adjacent to the RXXR site (between residues 188 and 202) were required for full bioactivity. In summary, we report a novel TC mutation and demonstrate a common defect of reduced FGF23 stability for all known FGF23-TC mutants. Finally, the majority of the COOH-terminal tail of FGF23 is not required for protein secretion but is required for full bioactivity.

AB - Fibroblast growth factor 23 (FGF23) is a hormone required for normal renal phosphate reabsorption. FGF23 gain-of-function mutations result in autosomal dominant hypophosphatemic rickets (ADHR), and FGF23 loss-of-function mutations cause familial hyperphosphatemic tumoral calcinosis (TC). In this study, we identified a novel recessive FGF23 TC mutation, a lysine (K) substitution for glutamine (Q) (160 C > A) at residue 54 (Q54K). To understand the molecular consequences of all known FGF23-TC mutants (H41Q, S71G, M96T, S129F, and Q54K), these proteins were stably expressed in vitro. Western analyses revealed minimal amounts of secreted intact protein for all mutants, and ELISA analyses demonstrated high levels of secreted COOH-terminal FGF23 fragments but low amounts of intact protein, consistent with TC patients' FGF23 serum profiles. Mutant protein function was tested and showed residual, yet decreased, bioactivity compared with wildtype protein. In examining the role of the FGF23 COOH-terminal tail (residues 180-251) in protein processing and activity, truncated mutants revealed that the majority of the residues downstream from the known FGF23 SPC protease site (176RXXR179/S 180) were not required for protein secretion. However, residues adjacent to the RXXR site (between residues 188 and 202) were required for full bioactivity. In summary, we report a novel TC mutation and demonstrate a common defect of reduced FGF23 stability for all known FGF23-TC mutants. Finally, the majority of the COOH-terminal tail of FGF23 is not required for protein secretion but is required for full bioactivity.

KW - Fibroblast growth factor 23

KW - Hyperphosphatemia

KW - Klotho

KW - Phosphate

UR - http://www.scopus.com/inward/record.url?scp=56049106116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049106116&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.90456.2008

DO - 10.1152/ajpendo.90456.2008

M3 - Article

C2 - 18682534

AN - SCOPUS:56049106116

VL - 295

SP - E929-E937

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1849

IS - 4

ER -